Alberto Lorenzatti

26.3k total citations · 4 hit papers
29 papers, 9.5k citations indexed

About

Alberto Lorenzatti is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Economics and Econometrics. According to data from OpenAlex, Alberto Lorenzatti has authored 29 papers receiving a total of 9.5k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Surgery, 10 papers in Endocrinology, Diabetes and Metabolism and 7 papers in Economics and Econometrics. Recurrent topics in Alberto Lorenzatti's work include Lipoproteins and Cardiovascular Health (19 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (8 papers) and Health Systems, Economic Evaluations, Quality of Life (7 papers). Alberto Lorenzatti is often cited by papers focused on Lipoproteins and Cardiovascular Health (19 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (8 papers) and Health Systems, Economic Evaluations, Quality of Life (7 papers). Alberto Lorenzatti collaborates with scholars based in Argentina, United States and Canada. Alberto Lorenzatti's co-authors include Paul M. Ridker, Francisco Antônio Helfenstein Fonseca, Robert J. Glynn, Antonio M. Gotto, John J.P. Kastelein, James Shepherd, Wolfgang Köenig, Jacques Genest, Peter Libby and James T. Willerson and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Alberto Lorenzatti

28 papers receiving 9.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

2008 4.7k citations Paul M. Ridker, Eleanor Danielson et al. New England Journal of Medicine profile →
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein

2009 2.9k citations Paul M. Ridker, Eleanor Danielson et al. Obstetrical & Gynecological Survey profile →
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

2009 751 citations Paul M. Ridker, Eleanor Danielson et al. The Lancet profile →
A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism

2009 543 citations Robert J. Glynn, Eleanor Danielson et al. New England Journal of Medicine profile →

Peers

Alberto Lorenzatti

SURGE

CCM

EDM

EPIDE

Eleanor Danielson United States

Francisco Antônio Helfenstein Fonseca Brazil

Gregory G. Schwartz United States

Michael Clearfield United States

Jean MacFadyen United States

Maurizio Averna Italy

Heinz Drexel Austria

G. Kees Hovingh Netherlands

John R. Downs United States

Olov Wiklund Sweden

Eleanor Danielson United States

Alberto Lorenzatti

5.6k ×1.0

SURGE

2.8k ×1.0

CCM

2.2k ×1.0

EDM

1.9k ×1.0

EPIDE

1.5k ×0.9

Citations per year, relative to Alberto Lorenzatti Alberto Lorenzatti (= 1×) peers Eleanor Danielson

Countries citing papers authored by Alberto Lorenzatti

Since Specialization

Citations

This map shows the geographic impact of Alberto Lorenzatti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alberto Lorenzatti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alberto Lorenzatti more than expected).

Fields of papers citing papers by Alberto Lorenzatti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alberto Lorenzatti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alberto Lorenzatti. The network helps show where Alberto Lorenzatti may publish in the future.

Co-authorship network of co-authors of Alberto Lorenzatti

This figure shows the co-authorship network connecting the top 25 collaborators of Alberto Lorenzatti. A scholar is included among the top collaborators of Alberto Lorenzatti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alberto Lorenzatti. Alberto Lorenzatti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Santi, Ricardo López, Daniel Piskorz, Sebastián García-Zamora, et al.. (2022). The Attitudes of Physicians Toward Guideline Recommendations for the Management of Dyslipidemia in Clinical Practice - The VIPFARMA ISCP Project. Current Problems in Cardiology. 48(1). 101434–101434. 1 indexed citations

Santi, Ricardo López, Felipe A. Martínez, Adrián Baranchuk, et al.. (2021). Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project. European Cardiology Review. 16. e16–e16. 1 indexed citations

Zapata, Gerardo, et al.. (2021). RACCOVID-19: primer Registro Argentino de Complicaciones Cardiovasculares en pacientes con COVID-19. 89(4). 285–292. 2 indexed citations

Santos, Raúl D., Alberto Lorenzatti, Pablo Corral, et al.. (2021). Challenges in familial chylomicronemia syndrome diagnosis and management across Latin American countries: An expert panel discussion. Journal of clinical lipidology. 15(5). 620–624. 5 indexed citations

Santi, Ricardo López, Manlio F. Márquez, Daniel Piskorz, et al.. (2021). Ambulatory Patients with Cardiometabolic Disease and Without Evidence of COVID-19 During the Pandemic. The CorCOVID LATAM Study. Global Heart. 16(1). 15–15. 7 indexed citations

Ponte‐Negretti, Carlos I., Fernando Wyss, Daniel Piskorz, et al.. (2021). Considerations and Guidance for the Structure, Organisation, and Operation of Cardiometabolic Prevention Units: A Consensus Statement of the Inter-American Society of Cardiology. Global Heart. 16(1). 27–27. 1 indexed citations

Lorenzatti, Alberto, et al.. (2019). New evidence on the role of inflammation in CVD risk. Current Opinion in Cardiology. 34(4). 418–423. 30 indexed citations

Santi, Ricardo López, Sohaib Haseeb, Bryce Alexander, et al.. (2018). Attitudes and Recommendations of Physicians towards Alcohol Consumption and Cardiovascular Health: A Perspective from Argentina. SHILAP Revista de lepidopterología. 6(3). 77–77. 7 indexed citations

Martin, Seth S., Robert P. Giugliano, Sabina A. Murphy, et al.. (2018). Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation. JAMA Cardiology. 3(8). 749–749. 99 indexed citations

10.

Lorenzatti, Alberto, et al.. (2018). Role of Anti-inflammatory Interventions in Coronary Artery Disease: Understanding the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). European Cardiology Review. 13(1). 38–38. 18 indexed citations

11.

Ponte‐Negretti, Carlos I., Fernando Laņas, Jesús Medina, et al.. (2017). Dislipidemia aterogénica en Latinoamérica: prevalencia, causas y tratamiento. Un consenso. 28(2). 54–85.

12.

Ponte‐Negretti, Carlos I., Fernando Laņas, Enrique Morales, et al.. (2017). Atherogenic dyslipidemia in Latin America: prevalence, causes and treatment. Consensus. 28(2). 57–85. 6 indexed citations

13.

Lorenzatti, Alberto, et al.. (2016). Unmet needs in the management of atherosclerotic cardiovascular disease: Is there a role for emerging anti-inflammatory interventions?. International Journal of Cardiology. 221. 581–586. 14 indexed citations

14.

Santos, Raúl D., et al.. (2011). Clinical perspective: Have the results of recent clinical trials of lipid-lowering therapies influenced the way we should practice? A Latin American perspective of current issues in clinical lipidology. Journal of clinical lipidology. 5(3). 124–132. 3 indexed citations

15.

Albert, Michelle A., Robert J. Glynn, Francisco Antônio Helfenstein Fonseca, et al.. (2011). Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. American Heart Journal. 162(1). 106–114.e2. 37 indexed citations

16.

Ridker, Paul M., Eleanor Danielson, Francisco Antônio Helfenstein Fonseca, et al.. (2009). Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein. Obstetrical & Gynecological Survey. 64(3). 168–170. 2948 indexed citations breakdown →

17.

Glynn, Robert J., Eleanor Danielson, Francisco Antônio Helfenstein Fonseca, et al.. (2009). A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism. New England Journal of Medicine. 360(18). 1851–1861. 543 indexed citations breakdown →

18.

Ridker, Paul M., Eleanor Danielson, Francisco Antônio Helfenstein Fonseca, et al.. (2009). Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. The Lancet. 373(9670). 1175–1182. 751 indexed citations breakdown →

19.

Ridker, Paul M., Eleanor Danielson, Francisco Antônio Helfenstein Fonseca, et al.. (2008). Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine. 359(21). 2195–2207. 4712 indexed citations breakdown →

20.

Ridker, Paul M., Francisco Antônio Helfenstein Fonseca, Jacques Genest, et al.. (2007). Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein. The American Journal of Cardiology. 100(11). 1659–1664. 96 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact